Photo of Rochelle G. Scheib, MD

Rochelle G. Scheib, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Photo of Rochelle G. Scheib, MD

Dana-Farber Cancer Institute

Visualize Collaborations

Rochelle G. Scheib, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Medical Oncologist, Gilette Center for Women's Cancers, Dana-Farber Cancer Institute

HCC PROGRAM AFFILIATION

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Bychkovsky B, Laws A, Katlin F, Hans M, Knust Graichen M, Pace LE, Scheib R, Garber JE, King TA. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Res Treat 2022. PubMed
  • Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, Garber JE, Morganstern D, King TA. Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Res Treat 2019. PubMed
  • Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat 2014. PubMed
  • Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006; 24:5330-1. PubMed
Visualize Collaborations